GE Healthcare Release: Noninvasive ExAblate(R) Treatment for Uterine Fibroids is Cost-Effective, New Study Says

WAUKESHA, Wis. & TIRAT CARMEL, Israel--(BUSINESS WIRE)--GE Healthcare and InSightec announced that new data show that the non-invasive ExAblate® 2000 Magnetic Resonance-guided Focused Ultrasound (MRgFUS) system is more cost-effective than myomectomy or Uterine Artery Embollization (UAE). The study appears in the January 2009 issue (Vol. 25, Issue 1) of The International Journal of Technology Assessment in Health Care.

MORE ON THIS TOPIC